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Background
Familial amyloidotic polyneuropathy (FAP) is a progressive
and fatal, autosomal dominant disease caused by deposi-
tion of mutant and wild-type transthyretin (TTR).
Patisiran is an investigational, systemically administered
lipid nanoparticle (LNP) formulation of a small interfering
RNA (siRNA) targeting wild-type and mutant TTR. This
formulation delivers the siRNA predominantly to the liver,
thereby inhibiting synthesis of TTR at the primary site of
production. A recently completed multi-center, multi-dose
Phase 2 trial of patisiran in FAP patients (N=29) showed
>80% sustained mean knockdown of serum TTR when
administered at a dose of 0.3 mg/kg every 3 weeks with a
generally favorable safety profile (Suhr O, ISA 2014).
Methods
A Phase 2 open-label extension (OLE) study of patisiran in
patients with FAP who participated in the aforementioned
trial, was initiated in October 2013. The primary objective
of the study is to evaluate the safety and tolerability of
0.3 mg/kg patisiran administered intravenously once every
3 weeks for up to 2 years. Secondary objectives include
assessment of patisiran’s effect on serum TTR levels, as
well as evaluation every 6 months of its impact on clinical
measures, including the mNIS+7 composite neurologic
impairment score and quality of life (QOL).
Results
Twenty-seven patients were enrolled; median age
64 years (range: 29-77 years). Chronic dosing with pati-
siran has been generally well tolerated. Three patients
experienced serious adverse events unrelated to study
drug. Flushing and infusion-related reactions were
observed in 22.2% and 18.5% of the patients, respec-
tively; these were mild in severity, and did not result in
any discontinuations. Sustained mean serum TTR lower-
ing of approximately 80% was achieved, with further
mean nadir of up to 88% between doses for approxi-
mately 16 months. Stabilization of quality of life (QOL)
measures was observed. Among the 20 evaluable
patients at the time of data cutoff, neuropathy impair-
ment scores were stable through 12 months with a
mean change in mNIS+7 and NIS of -2.5 and 0.4 points,
respectively; this compares favorably to the 10-18 point
increase in neurologic impairment scores estimated at
12 months from prior FAP studies in a patient popula-
tion with similar baseline NIS.
Conclusion
Data from this Phase 2 OLE study demonstrate that
12-months of patisiran administration was well-toler-
ated, resulted in sustained mean serum TTR lowering,
and has the potential to halt neuropathy progression. As
of March 2015, dosing continues for all patients;
18-month results will be presented.
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